ArticlePharmaceutics2022
Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Linker Chemistry in Radiopharmaceutical Design.Bioconjugate chemistry · 2026Review
- Enhanced Radionuclide Therapy via the Conjugation of Pentadecanoic Acids WithCancer science · 2026Article
- Review
- A Novel FAPI-Based Radiopharmaceutical for SPECT Imaging of Fibrotic Interstitial Lung Disease.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Development of Novel Integrin αACS medicinal chemistry letters · 2025Article
- Radioiodinated Bicyclic RGD Peptide Derivatives for Enhanced Tumor Accumulation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Safety, pharmacokinetics, and dosimetry ofActa pharmaceutica Sinica. B · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Peptide receptor radionuclide therapy (PRRT) is an emerging approach for patients with unresectable or metastatic tumors. Our previously optimized RGD peptide (3PRGD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.